

## **CORRIGENDUM**

# *Progress and prospects: Immunobiology of gene therapy for neurodegenerative disease: prospects and risks*

MM McMEnamin and MJA Wood

Gene Therapy (2010) 17, 690; doi:10.1038/gt.2010.67

**Correction to:** Gene Therapy (2010) 17, 592–605; doi:10.1038/gt.2010.2; published online 11 February 2010

The authors have discovered an error that they would like to correct. The paragraph describing the work of the authors cited in Reference 80 (Madsen *et al. J Gen Virol* 2009; 90 (Pt 11): 2622–2633) was accidentally omitted. This paragraph should read as follows:

In a recent detailed examination of AAV2 immunity in humans, cell-mediated and humoral immune responses

to AAV2 were characterized from a panel of healthy blood donors. Over 90% were seropositive and cell-mediated immune recall responses were detectable in nearly half of the population studied. However, vector delivery to the CNS may nonetheless escape antigen presentation and avoid this immunological memory.'

The authors apologize for this error.